SAN DIEGO, May 18, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that a new publication from the large Women & Infants multi-center clinical study on the Sequenom Center for Molecular Medicine's (Sequenom CMM) MaterniT21 PLUS laboratory-developed test (LDT) has been published online in the peer-reviewed journal, Prenatal Diagnosis. Along with this week's publication, the Company announces that as of the week ended May 12, 2012, Sequenom CMM has processed more than 10,000 commercial MaterniT21 PLUS test samples in 2012.The publication addresses the capability of the MaterniT21 PLUS LDT to accurately detect the presence of certain fetal trisomies in pregnant women carrying twins or triplets. The paper will appear in the journal's May issue and the full abstract can be found online at: http://onlinelibrary.wiley.com/doi/10.1002/pd.3892/abstract. "The underlying biology and these positive...
Read More >>
SAN DIEGO, May 17, 2012 /PRNewswire/ -- Sequenom Inc., (NASDAQ: SQNM) through its wholly owned subsidiary Sequenom Center for Molecular Medicine, LLC, (Sequenom CMM) entered into the recently announced provider network participation agreement with Coventry Health Care National Network, Inc. on May 4, 2012. The agreement included an effective date of July 1, 2012 for Sequenom CMM's participation in provider networks offered and sold by Coventry. On May 14, 2012, Sequenom CMM received a written notice from Coventry Health Care, Inc. on behalf of itself and its affiliates, including Coventry Health Care National Network, Inc., terminating the agreement without cause as provided for in the agreement, effective August 31, 2012. Coventry advised Sequenom CMM that this decision was not a judgment on Sequenom, Inc., Sequenom CMM or its products. The agreement was intended to provide members in the network with coverage for Sequenom CMM's MaterniT21 PLUS laboratory-developed test (LDT) and...
Read More >>
SAN DIEGO, May 7, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced the Company's participation at the Bank of America Merrill Lynch Health Care Conference at the Encore at the Wynn Hotel in Las Vegas, NV on May 15-17, 2012. Ronald M. Lindsay, Ph.D., Director and EVP of Research and Development, will present on Tuesday, May 15, 2012 beginning at 1:00 p.m. PDT, to provide an overview of and update on the Company. The presentation is expected to last approximately 30 minutes and will be webcast live through the "Investors" section of the Sequenom website at www.sequenom.com. An audio replay will be available for 30 days following the initial presentation webcast. About SequenomSequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that...
Read More >>
SAN DIEGO, May 3, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today reported revenue of $14.9 million for the first quarter of 2012, an increase of 10% compared to revenue of $13.5 million for the first quarter of 2011. First quarter 2012 revenues from the Sequenom Center for Molecular Medicine (Sequenom CMM) diagnostics services operating segment grew more than 187%, while revenues from the genetic analysis operating segment decreased 14% in the first quarter of 2012 as compared to the prior year period. Net loss for the first quarter of 2012 was $24.5 million, or $0.22 per share, as compared to net loss of $12.7 million, or $0.13 per share for the same period in 2011, reflecting an increase in costs associated primarily with the early commercialization of the Sequenom CMM MaterniT21™ PLUS laboratory developed test (LDT).As to be expected in the first year following the launch of a new LDT, gross...
Read More >>
SAN DIEGO, April 19, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced an agreement with MultiPlan, Inc., the nation's leading provider of healthcare cost management solutions (PHCS). Under this expanded agreement, Sequenom's participation in the PHCS and MultiPlan networks will now include its Center for Molecular Medicine's MaterniT21 PLUS™ laboratory-developed test to detect certain fetal trisomies in women at increased risk of carrying a child with one of these chromosomal abnormalities. More than 900,000 providers participate in MultiPlan's networks."We are very pleased to extend our relationship with MultiPlan, giving their clients' members and their network of participating providers access to the MaterniT21 PLUS test," said Harry F. Hixson, Jr., Ph.D., Chairman and CEO, Sequenom, Inc. "Of the many important decisions to make in a high-risk pregnancy, the coverage of a valuable...
Read More >>
SAN DIEGO, April 17, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced it has extended the term of a supply agreement with Illumina, Inc., a leading developer and manufacturer of life sciences tools and integrated systems for the large scale-analysis of genetic variation and function.The amendment extends the term of the supply agreement from three years to five years, terminating in July 2016. Sequenom and its subsidiaries purchase Illumina's sequencing equipment and consumables for use in the cell-free detection of fetal chromosomal abnormalities in maternal blood. About SequenomSequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was...
Read More >>
SAN DIEGO, April 16, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today reported that more than 12,700 total tests, including in excess of 4,900 MaterniT21 PLUS laboratory-developed tests (LDT) offered by Sequenom Center for Molecular Medicine (Sequenom CMM), were accessioned during the first quarter of 2012. This equates to an annualized run rate in excess of 30,000 MaterniT21 PLUS LDTs, based on the volume processed during the last week of the quarter. Due to the successful growth in adoption year-to-date, the Company is increasing its internal goal to 40,000 MaterniT21 PLUS LDTs billed in 2012, up from the original goal of 25,000 tests billed for the year. "After the successful launch of the MaterniT21 PLUS LDT in 2011, Sequenom CMM has experienced growing demand for the test and weekly increases in samples received and billed during the early part of 2012," said Harry F. Hixson, Chairman and CEO of...
Read More >>
SAN DIEGO, Calif., March 8, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced the Company's participation at the Barclays Global Healthcare Conference at the Loews Miami Hotel in Miami, FL on March 13-14, 2012.Ronald M. Lindsay, Ph.D., Director and EVP of Research and Development, will present on Wednesday, March 14, 2012 beginning at 4:15 p.m. ET, to provide an overview of and update on the Company. The presentation is expected to last approximately 30 minutes and will be web cast live through the "Investors" section of the Sequenom website at www.sequenom.com. An audio replay will be available for 30 days following the initial presentation web cast.About SequenomSequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and...
Read More >>
SAN DIEGO, March 7, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today reported total revenues of $15.5 million and $55.9 million for the fourth quarter and full-year of 2011, respectively. Net loss was $22.2 million, or $0.22 per share, and $74.2 million, or $0.75 per share, for the fourth quarter and full-year, respectively. "2011 was a pivotal year for Sequenom as the Sequenom Center for Molecular Medicine launched its cornerstone MaterniT21™ prenatal laboratory-developed test and advanced a number of other important programs," said Harry F. Hixson, Chairman and CEO of Sequenom, Inc. "The positive uptake from the launch of the MaterniT21 LDT and increasing early volumes for testing services since has set the tone for our expected growth and expansion during 2012."Fourth Quarter 2011 PerformanceFourth quarter revenues of $15.5 million in 2011 increased 13% over revenues of $13.8 million for the...
Read More >>
SAN DIEGO, March 5, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced the Company's participation at the 24th Annual Roth OC Growth Stock Conference at the Ritz-Carlton Hotel in Laguna Niguel, CA on March 11-14, 2012. Dirk van den Boom, Ph.D., SVP of Research and Development, will present on Monday, March 12, 2012 beginning at 5:00 p.m. PT, to provide an overview of and update on the Company. The presentation is expected to last approximately 30 minutes and will be web cast live through the "Investors" section of the Sequenom website at www.sequenom.com. An audio replay will be available for 30 days following the initial presentation web cast. About SequenomSequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve...
Read More >>
SAN DIEGO, Feb. 22, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that it has filed a motion for preliminary injunction against Aria Diagnostics ("Aria") to stop Aria from making, using, selling or offering for sale, importing or exporting, infringing tests for detecting fetal chromosomal aneuploidy, such as Aria's Harmony Prenatal Test™, pending the ultimate resolution of the litigation.Sequenom's request for preliminary injunction follows the lawsuit filed on January 24, 2012, in the United States District Court for the Southern District of California, which alleges that Aria infringes U.S. Patent No. 6,258,540 ("'540 patent"). Sequenom is requesting that the district court quickly intervene to stop Aria Diagnostics' continued infringement of the '540 patent.Sequenom Center for Molecular Medicine (Sequenom CMM) was the first to market a non-invasive prenatal diagnostics laboratory...
Read More >>
SAN DIEGO, Feb. 22, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced it will report financial results for the fourth quarter and full-year 2011 after closing of the NASDAQ Global Market on Wednesday, March 7, 2012.A conference call hosted by Harry F. Hixson, Jr., Ph.D., Chairman and CEO, and other members of senior management will take place on the same day at 5:00pm, ET (2:00pm PT) and will be webcast live on the Sequenom website. To access the live teleconference call, dial 800-860-2442 in the U.S., 866-605-3852 in Canada (both are toll free), and 412-858-4600 for other international callers. Please specify to the operator that you would like to join the "Sequenom Fourth Quarter and Full-Year 2011 Earnings Conference Call." If you are unable to listen to the live webcast, a teleconference replay will be available through Thursday, March 15, 2012. Interested parties can access the...
Read More >>
SAN DIEGO, Feb. 8, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that its wholly-owned subsidiary, the Sequenom Center for Molecular Medicine (Sequenom CMM), has expanded the application of its recently launched laboratory-developed test (LDT). The Company also announced it has rebranded the test under the name MaterniT21 PLUS, which includes the detection of trisomies 18 and 13 in addition to trisomy 21.The MaterniT21 PLUS test provides direct assessment of fetal chromosomal status by analyzing cell-free DNA in a maternal blood sample. The clinical validation results describing the test's ability to accurately detect trisomy 21 were published in the journal Genetics in Medicine in October 2011, and a new analysis on the detection of trisomy 18 and 13 has been published online, and will be available in the journal's March 2012 issue. The published research to date...
Read More >>
SAN DIEGO, Feb. 2, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that a new publication of an independent multi-center study on Sequenom Center for Molecular Medicine's MaterniT21™ laboratory-developed test (LDT) appears today in the online issue of Genetics in Medicine. The study demonstrated the LDT can detect fetal trisomy 21, 18 and 13 with high accuracy from a maternal blood sample and will be published in the March issue. The full results of the study can be found online at http://journals.lww.com/geneticsinmedicine/."Together with the previously published results on the test's ability to detect trisomy 21 with high accuracy, this publication provides further evidence that this valuable non-invasive technology can identify nearly all cases of T18 and T13, as well as T21, at a low false positive rate," said Harry F. Hixson, Jr., Ph.D., Chairman and CEO, Sequenom, Inc. "This research...
Read More >>
SAN DIEGO, Jan. 25, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM) today announced the completion of an underwritten public offering of 14,950,000 shares of its common stock, including 1,950,000 shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriters. All of the shares were offered by Sequenom at a price to the public of $4.15 per share. The gross proceeds to Sequenom from this offering were approximately $62.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Sequenom. Sequenom anticipates using the net proceeds from the offering for general corporate purposes, including research and development expenses, capital expenditures, working capital and general administrative expenses. Jefferies & Company, Inc. acted as sole book-running manager for the offering, and Oppenheimer & Co. Inc. and William Blair & Company, L.L.C. acted as co-managers for the offering...
Read More >>
SAN DIEGO, Jan. 20, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM) today announced the pricing of an underwritten public offering of 13,000,000 shares of its common stock, offered at a price to the public of $4.15 per share. The gross proceeds to Sequenom from this offering are expected to be $53.95 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Sequenom. Sequenom has granted the underwriters a 30-day option to purchase up to an aggregate of 1,950,000 additional shares of common stock to cover over-allotments, if any. The offering is expected to close on or about January 25, 2012, subject to customary closing conditions. Sequenom anticipates using the net proceeds from the offering for general corporate purposes, including research and development expenses, capital expenditures, working capital and general administrative expenses. Jefferies & Company, Inc. is acting as sole book-running manager for the offering...
Read More >>
SAN DIEGO, Jan. 19, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.Jefferies & Company, Inc. is acting as sole book-running manager for the offering. The securities described above are being offered by Sequenom pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission (the "SEC"), which the SEC declared effective on December 21, 2011. A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering, when available, may be obtained from Jefferies & Company...
Read More >>
SAN DIEGO, Jan. 8, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced highlights of the Company's 2011 performance and accomplishments, as well as preliminary activities and goals for the first part of 2012. Initial 2011 Performance ResultsTotal revenue growth of approximately 23 percent year-over-year for 2011 (unaudited). Over 21,000 total prenatal and retinal diagnostic tests were billed during the year. Sales in the Genetic Analysis business segment were up approximately 6 percent from 2010. (unaudited), each quarter improving over the same period in the prior year. Positive results following the October 2011 launch of Sequenom Center for Molecular Medicine's (Sequenom CMM) MaterniT21 laboratory developed test (LDT):
The MaterniT21 LDT is now available for sale through Sequenom CMM in all 50 states in the U.S., including New York. The Company received its first payments as an out-of...
Read More >>
SAN DIEGO, Jan. 5, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced the Company's participation at the 30th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on January 9-12, 2012. Harry F. Hixson, Jr, Ph.D., Chairman and CEO, and Ronald M. Lindsay, Ph.D., Director and EVP of Research and Development, will present on Thursday, January 12, 2012 beginning at 7:30 a.m. PT, to provide an overview of and update on the Company. The presentation is expected to last approximately 30 minutes and will be web cast live through the "Investors" section of the Sequenom website at www.sequenom.com. An audio replay will be available for 30 days following the initial presentation web cast. About SequenomSequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops...
Read More >>
SAN DIEGO, Dec. 19, 2011 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that numerous leading healthcare providers across the United States, including Women & Infants Hospital of Rhode Island, Vanderbilt University Medical Center, and Florida Hospital in Orlando have begun ordering the Sequenom Center for Molecular Medicine's (Sequenom CMM) MaterniT21 laboratory-developed test (LDT) for their patients. The MaterniT21 LDT provides direct assessment of fetal chromosomal status by examining circulating cell-free DNA in a maternal blood sample.Women & Infants Hospital participated in the validation study of the MaterniT21 LDT that detects a genetic chromosomal anomaly known as Trisomy 21, the most common cause of Down syndrome. The results of this international, multicenter study were published online on October 17, 2011 in the journal Genetics in Medicine. "Based on our participation in the...
Read More >>
SAN DIEGO, Dec. 15, 2011 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that the company has been upgraded to the NASDAQ Global Select Market, a segment of the NASDAQ Global Market with the highest initial listing standards of any exchange in the world. Sequenom will continue to trade under the ticker symbol, "SQNM," and will transfer its stock listing starting on January 3, 2012."As Sequenom continues to advance its mission of improving healthcare through revolutionary genetic analysis, we appreciate the opportunity to be recognized among the most innovative companies in the world on the NASDAQ Global Select Market," said Harry F. Hixson, Jr., Ph.D., Chairman and CEO, Sequenom. About SequenomSequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic...
Read More >>
SAN DIEGO, Dec. 5, 2011 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced the Company's participation at the 22nd Annual Oppenheimer Healthcare Conference at the Waldorf Astoria Hotel in New York City December 13-14, 2011. Ronald M. Lindsay, Ph.D., Director and EVP of Research will present on Wednesday, December 14, 2011 beginning at 1:35 p.m. ET, to provide an overview of and update on the Company. The presentation is expected to last approximately 30 minutes and will be web cast live through the "Investors" section of the Sequenom website at www.sequenom.com. An audio replay will be available for 30 days following the initial presentation web cast. About SequenomSequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve...
Read More >>
SAN DIEGO, Nov. 22, 2011 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced the Company's participation at the 23rd Annual Piper Jaffray Healthcare Conference at the Palace Hotel in New York City November 29-30, 2011. Ronald M. Lindsay, Ph.D., Director and EVP of Research and Development and Paul V. Maier, CFO, will present on Tuesday, November 29, 2011 beginning at 8:30 a.m. ET, to provide an overview of and update on the Company. The presentation is expected to last approximately 30 minutes and will be web cast live through the "Investors" section of the Sequenom website at www.sequenom.com. An audio replay will be available for 30 days following the initial presentation web cast. About SequenomSequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and...
Read More >>
SAN DIEGO, Nov. 14, 2011 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that it will host an Investor and Analyst Day at NASDAQ Tower in New York on Monday, November 14, 2011 from 2:00 to 5:00 pm ET. Key members of the company's management team will offer an in-depth discussion of the business, specifically focusing on the recent commercial launch of the MaterniT21 laboratory developed test (LDT). Space for the event is limited and, therefore, by invitation only. For those who cannot attend, the presentation will be web cast live through the "Investor Relations" section of the Sequenom website at www.sequenom.com. An audio replay will be available for 30 days following the initial presentation web cast. About SequenomSequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative...
Read More >>
SAN DIEGO, Nov. 10, 2011 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced the Company's participation at the Lazard Capital Markets 8th Annual Healthcare Conference at the Pierre Hotel in New York City November 15-16, 2011.Harry F. Hixson, Jr, Ph.D., Chairman and CEO, and Ronald M. Lindsay, Ph.D., Director and EVP of Research and Development, will present on Tuesday, November 15, 2011 beginning at 8:30 a.m. ET, to provide an overview of and update on the Company. The presentation is expected to last approximately 30 minutes and will be web cast live through the "Investors" section of the Sequenom website at www.sequenom.com. An audio replay will be available for 30 days following the initial presentation web cast.About SequenomSequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative...
Read More >>
News Release Archive >>
|